Clinical trial NCT06870890: Impact of Sarcopenia on Dyspnea in Patients With Asthma
Official title: Impact of Sarcopenia on Dyspnea in Patients With Asthma
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Sarcopenia
Asthma
Dyspnea
Dyspnea; Asthmatic
Cytokines
Adipokines
Myokine
Muscle Disorder
Keywords: Asthma
Sarcopenia
Dyspnea
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
First posted: 2025-03-11
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Dyspnea in asthma, is mainly due to airway obstruction but can be caused by several alternative diagnoses.

The impact of sarcopenia on dyspnea in patients with asthma is unknown. Sarcopenic asthma had a reduced physical activity and is associated with airway obstruction compared to non-sarcopenic asthma. In patients with obstructive pulmonary disease, sarcopenia is associated with shallow breathing and diverse sensory and affective components of exertional dyspnea .

The morbidity of sarcopenia is also increased by systemic inflammation and the production of inflammatory cytokines as found in inflammatory airway obstruction.

The investigators will investigate the prevalence and impact of sarcopenia in asthmatics patients. This will enable to better manage sarcopenia in asthmatic patients, understand its origins and personalize treatment.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years
* Patient affiliated to a social security scheme.
* Patient capable of giving free, informed, written and signed consent.
* Asthmatic patients with a diagnosis made by a pulmonologist on GINA level 4 or 5 treatment
* ACT asthma control score \< 20
* Patient judged by the investigator to be able to to perform a maximal exercise test.

Exclusion Criteria:

* Patient under guardianship/trusteeship/supervision of justice
* Pregnant or breast-feeding women
* Unstable heart disease
* Patients who have been smoking or have stopped smoking for less than 5 years,

Primary outcomes:
measure: Variation in the intensity of dyspnea during exercise mesured with Borg scale (0-10) according to the presence of sarcopenia
timeFrame: From baseline (at rest) to the end of the exercise
Secondary outcomes:
measure: Variation in exercise-induced release of biomarkers according to the presence of sarcopenia
timeFrame: at rest = baseline / right after the end of exercice / 45 minutes after the end of exercice
measure: Difference in muscle mass (kg) on impedancemetry according to the presence of sarcopenia
timeFrame: Baseline
measure: Difference on maximum aerobic capacity (VO2 max in L/mn) , according to the presence of sarcopenia
timeFrame: immediately after the exercise test
measure: Difference in fat mass (kg) on impedancemetry according to the presence of sarcopenia
timeFrame: At baseline
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: CHU Clermont-Ferrand
Study officials:
affiliation: University Hospital, Clermont-Ferrand
name: Camille ROLLAND-DEBORD
role: PRINCIPAL_INVESTIGATOR
References: